Working… Menu

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03599453
Recruitment Status : Recruiting
First Posted : July 25, 2018
Last Update Posted : November 8, 2019
National Cancer Institute (NCI)
Hemispherx Biopharma
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 6, 2021
Estimated Study Completion Date : July 6, 2022